- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Therapies for Pemphigus Vulgaris
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-29
DOI
10.1007/s40257-020-00544-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tirabrutinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
- (2019) Andres Forero-Torres et al. BLOOD
- ST18 Enhances PV-IgG-Induced Loss of Keratinocyte Cohesion in Parallel to Increased ERK Activation
- (2019) Mariya Y. Radeva et al. Frontiers in Immunology
- Current Clinical Trials in Pemphigus and Pemphigoid
- (2019) Kentaro Izumi et al. Frontiers in Immunology
- Rituximab is an Effective Treatment in Patients with Pemphigus Vulgaris and Demonstrates a Steroid‐Sparing Effect
- (2019) D.M. Chen et al. BRITISH JOURNAL OF DERMATOLOGY
- Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
- (2019) Carolyn J. Kushner et al. JAMA Dermatology
- Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience
- (2018) Susan O’Brien et al. BLOOD
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Rituximab in pemphigus
- (2018) Vivien Hebert et al. Immunotherapy
- 538 FcRn blockade with SYNT001 for the treatment of pemphigus
- (2018) V.P. Werth et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- 461 Preclinical development of desmoglein chimeric autoantibody receptor (CAAR) T cells for pemphigus therapy
- (2018) J. Lee et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts
- (2018) Dedee F. Murrell et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse Effects of Immunoglobulin Therapy
- (2018) Yi Guo et al. Frontiers in Immunology
- Pemphigus—A Disease of Desmosome Dysfunction Caused by Multiple Mechanisms
- (2018) Volker Spindler et al. Frontiers in Immunology
- A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials
- (2018) Henrieta Fraser et al. Molecular Therapy-Methods & Clinical Development
- Targeted Therapies for Autoimmune Bullous Diseases: Current Status
- (2018) Kyle T. Amber et al. DRUGS
- Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
- (2018) Peter Ulrichts et al. JOURNAL OF CLINICAL INVESTIGATION
- LB1509 Anti-desmoglein levels & response to the BTK inhibitor PRN1008 in pemphigus
- (2018) D. Murrell et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Kill ‘Em All: Efgartigimod Immunotherapy for Autoimmune Diseases
- (2018) Jagadeesh Bayry et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier
- (2018) Jonathan H. Esensten et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
- (2017) Pascal Joly et al. LANCET
- Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling
- (2017) Andrew T. Bender et al. MOLECULAR PHARMACOLOGY
- Mechanisms of Autoantibody-Induced Pathology
- (2017) Ralf J. Ludwig et al. Frontiers in Immunology
- Interleukin 4 inhibition as a potential therapeutic in pemphigus
- (2016) Soheil Tavakolpour et al. CYTOKINE
- Role of regulatory B cells in immune tolerance to allergens and beyond
- (2016) Willem van de Veen et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Future therapies for pemphigus vulgaris: Rituximab and beyond
- (2016) Amy Huang et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Like Angler Fish, CAARs Lure Their Prey
- (2016) Anne Galy MOLECULAR THERAPY
- Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
- (2016) C. T. Ellebrecht et al. SCIENCE
- Identification of a Functional Risk Variant for Pemphigus Vulgaris in the ST18 Gene
- (2016) Dan Vodo et al. PLoS Genetics
- Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials
- (2016) Emilia Quattrocchi et al. PLoS One
- SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic Exposure
- (2015) P.F. Smith et al. ANNALS OF THE RHEUMATIC DISEASES
- Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid
- (2015) Michael Mersmann et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Paradoxical worsening of pemphigus vulgaris following rituximab therapy
- (2015) R.J. Feldman BRITISH JOURNAL OF DERMATOLOGY
- Designing chimeric antigen receptors to effectively and safely target tumors
- (2015) Michael C Jensen et al. CURRENT OPINION IN IMMUNOLOGY
- The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis
- (2015) Lihi Atzmony et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial
- (2015) Peter Hillmen et al. LANCET
- First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids
- (2015) Saskia Ingen-Housz-Oro et al. JAMA Dermatology
- First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
- (2014) Y Cho et al. ACTA DERMATO-VENEREOLOGICA
- Impaired function of CD19+CD24hiCD38hiregulatory B cells in patients with pemphigus
- (2014) H.-Q. Zhu et al. BRITISH JOURNAL OF DERMATOLOGY
- PI3K inhibitors as potential therapeutics for autoimmune disease
- (2014) Jennifer Ball et al. DRUG DISCOVERY TODAY
- Activation of the JAK/STAT-1 Signaling Pathway by IFN- Can Down-Regulate Functional Expression of the MHC Class I-Related Neonatal Fc Receptor for IgG
- (2014) X. Liu et al. JOURNAL OF IMMUNOLOGY
- Pathogenic IgG Antibodies against Desmoglein 3 in Pemphigus Vulgaris Are Regulated by HLA-DRB1*04:02–Restricted T Cells
- (2014) Rüdiger Eming et al. JOURNAL OF IMMUNOLOGY
- Pemphigus. S2 Guideline for diagnosis and treatment - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)
- (2014) M. Hertl et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- GSK launches mega trial of p38 MAPK inhibitor in acute coronary syndrome
- (2014) NATURE REVIEWS DRUG DISCOVERY
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
- (2014) Christoph T. Ellebrecht et al. JAMA Dermatology
- Durable Remission of Pemphigus With a Fixed-Dose Rituximab Protocol
- (2014) Kara Heelan et al. JAMA Dermatology
- Analysis of High-dose Intravenous Immunoglobulin Therapy in 16 Patients with Refractory Autoimmune Blistering Skin Disease: High Efficacy and No Serious Adverse Events
- (2013) V Seidling et al. ACTA DERMATO-VENEREOLOGICA
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials
- (2013) Jan A. Burger Current Hematologic Malignancy Reports
- p38 mitogen-activated protein kinase (p38 MAPK)-mediated autoimmunity: Lessons to learn from ANCA vasculitis and pemphigus vulgaris
- (2012) Athanasios Mavropoulos et al. AUTOIMMUNITY REVIEWS
- Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: a meta-analysis
- (2012) L. Yan et al. BRITISH JOURNAL OF DERMATOLOGY
- The Immunologic Functions of the Neonatal Fc Receptor for IgG
- (2012) Timo Rath et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Population-Specific Association between a Polymorphic Variant in ST18, Encoding a Pro-Apoptotic Molecule, and Pemphigus Vulgaris
- (2012) Ofer Sarig et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Immunoadsorption in Dermatology
- (2012) Damian Meyersburg et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Central B-Cell Tolerance: Where Selection Begins
- (2012) R. Pelanda et al. Cold Spring Harbor Perspectives in Biology
- Regulatory T Cell-Mediated Control of Autoantibody-Induced Inflammation
- (2012) Keishi Fujio et al. Frontiers in Immunology
- Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
- (2011) M. H. Buch et al. ANNALS OF THE RHEUMATIC DISEASES
- Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial
- (2011) P. C. Taylor et al. ANNALS OF THE RHEUMATIC DISEASES
- The future of anti-CD20 monoclonal antibodies: are we making progress?
- (2011) W. Alduaij et al. BLOOD
- An Adult Passive Transfer Mouse Model to Study Desmoglein 3 Signaling in Pemphigus Vulgaris
- (2011) Katja Schulze et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus
- (2011) Linda K. Martin et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Neonatal Fc receptor and IgG-based therapeutics
- (2011) Timothy T. Kuo et al. mAbs
- Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells
- (2011) K. Baker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intravenous Immunoglobulin Therapy in Autoimmune Mucocutaneous Blistering Diseases
- (2010) Hakan M. Gürcan et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Immunoadsorption in dermatology
- (2010) Enno Schmidt et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- PI3K inhibition in inflammation: Toward tailored therapies for specific diseases
- (2010) Alessandra Ghigo et al. BIOESSAYS
- The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases
- (2010) Alina Sesarman et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells
- (2010) Rogier Kersseboom et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Structure and function of immunoglobulins
- (2010) Harry W. Schroeder et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- p38 MAPK Activation Is Downstream of the Loss of Intercellular Adhesion in Pemphigus Vulgaris
- (2010) Xuming Mao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
- (2010) David M. Goldenberg et al. LEUKEMIA & LYMPHOMA
- New Btk inhibitor holds promise
- (2010) Rudi W Hendriks Nature Chemical Biology
- Rituximab: Mechanism of Action
- (2010) George J. Weiner SEMINARS IN HEMATOLOGY
- Inhibitors of the FcRn:IgG Protein–Protein Interaction
- (2009) Susan C. Low et al. AAPS Journal
- Primary B Cell Immunodeficiencies: Comparisons and Contrasts
- (2009) Mary Ellen Conley et al. Annual Review of Immunology
- Rituximab inhibits B-cell receptor signaling
- (2009) S. Kheirallah et al. BLOOD
- BAFF: a local and systemic target in autoimmune diseases
- (2009) I. Moisini et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Immunogenicity of rituximab in patients with severe pemphigus
- (2009) Enno Schmidt et al. CLINICAL IMMUNOLOGY
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Involvement of TH1/TH2 Cytokines in the Pathogenesis of Autoimmune Skin Disease—Pemphigus Vulgaris
- (2009) Abhigyan Satyam et al. IMMUNOLOGICAL INVESTIGATIONS
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Molecular mechanism and function of CD40/CD40L engagement in the immune system
- (2009) Raul Elgueta et al. IMMUNOLOGICAL REVIEWS
- Desmocollin 3-mediated Binding Is Crucial for Keratinocyte Cohesion and Is Impaired in Pemphigus
- (2009) Volker Spindler et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A randomized double-blind trial of intravenous immunoglobulin for pemphigus
- (2009) Masayuki Amagai et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Targeting innate immunity protein kinase signalling in inflammation
- (2009) Matthias Gaestel et al. NATURE REVIEWS DRUG DISCOVERY
- B-Cell–Depleting Induction Therapy and Acute Cellular Rejection
- (2009) Menna R. Clatworthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- How do Regulatory T Cells Work?
- (2009) A. Corthay SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- p38MAPK: stress responses from molecular mechanisms to therapeutics
- (2009) Lydia R. Coulthard et al. TRENDS IN MOLECULAR MEDICINE
- Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin
- (2008) Paula Berkowitz et al. AMERICAN JOURNAL OF PATHOLOGY
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
- (2008) D. M. Goldenberg et al. BLOOD
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
- (2008) A. Hagenbeek et al. BLOOD
- Rituximab: Beyond Simple B Cell Depletion
- (2008) A. Kessel et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Rituximab Immunotherapy in Pemphigus: Therapeutic Effects Beyond B-Cell Depletion
- (2008) Giovanna Zambruno et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Rituximab Exerts a Dual Effect in Pemphigus Vulgaris
- (2008) Rüdiger Eming et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses
- (2008) Hugo Mouquet et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn
- (2008) A. R. Mezo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dependence of antibody-mediated presentation of antigen on FcRn
- (2008) S.-W. Qiao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More